Increased cardiovascular mortality associated with gout: A systematic review and meta-analysis

European Journal of Preventive Cardiology

Volumn 22, Issue 3, 2015, Pages 335-343

  Clarson, L E ^a   Chandratre, P ^a   Hider, S L ^a   Belcher, J ^a   Heneghan, C ^b   Roddy, E ^a   Mallen, C D ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiovascular disease; coronary heart disease; gout; mortality; myocardial infarction

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CINAHL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EMBASE; GOUT; HAZARD RATIO; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CORONARY DISEASE; MORTALITY; ODDS RATIO; PROGNOSIS; TIME;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CORONARY DISEASE; GOUT; HUMANS; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84922627510     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313514895     Document Type: Review

References (42)

1. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008 ; 67: 960-966
2. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 ; 63: 3136-3141
3. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010 ; 62: 170-180
4. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008 ; 59: 1690-1697
5. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011 ; 63: 3294-3304
6. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009 ; 68: 1131-1135
7. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011 ; 8: e1001098 - e1001098
8. Brook RD, Yalavarthi S, Myles JD, et al. Determinants of vascular function in patients with chronic gout. J Clin Hypertens (Greenwich). 2011 ; 13: 178-188
9. Roddy E, Menon A, Hall A, et al. Polyarticular sonographic assessment of gout: a hospital-based cross-sectional study. Joint Bone Spine. 80: 295-300
10. Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005 ; 165: 742-748
11. Choi HK, Curhan G. Independent impact of gout on mortality and risk of coronary heart disease. Circulation. 2007 ; 116: 894-900
12. Krishnan E, Svendsen K, Neaton JD,, et al. MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104-1110.
13. Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep. 2012 ; 14: 195-203
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005 ; 43: 1130-1139
15. Wells G, Shea A, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. Available at: www.ohri.ca/programs/clinical-epidemiology/oxford.htm (2008, consulted February 2013).
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7: 177-188
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 ; 21: 1539-1558
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 ; 50: 1088-1101
19. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple graphical test. Br Med J. 1997 ; 315: 629-634
20. Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010 ; 49: 141-146
21. Teng GG, Ang LW, Saag KG, et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. 2012 ; 71: 924-928
22. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006 ; 54: 2688-2696
23. DeVera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010 ; 69: 1162-1164
24. Cohen SD, Kimmel PL, Neff R, et al. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008 ; 19: 2204-2210
25. Mahmoodi BK, Matsushita K, Woodward M,, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380: 1649-1661.
26. Gaita D, Mihaescu A, Schiller A. Of heart and kidney: a complicated love story. Eur J Prev Cardiol. 2012 ;
27. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004 ; 24: 816-823
28. Jin M, Yang F, Yang I, et al. Uric acid, Hyperuricemia and vascular diseases. Front Biosci. 2012 ; 17: 656-669
29. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003 ; 41: 1287-1293
30. Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005 ; 16: 3553-3562
31. Hoieggen A, Alderman MH, Kjeldsen SE,, et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
32. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemia subjects with normal renal function. Clin J Am Soc Nephrol. 2011 ; 6: 1887-1894
33. Melendez-Ramirez G, Perez-Mendez O, Lopez-Osorio C, et al. Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. Endocr Res. 2012 ; 37: 1-6
34. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007 ; 39: 1227-1233
35. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010 ; 375: 2161-2167
36. Soltész P, Kerekes G, Dér H, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev. 2011 ; 10: 416-425
37. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991 ; 34: 141-145
38. Filippucci E, Scirè CA, Delle Sedie A, et al. Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease. Clin Exp Rheumatol. 2010 ; 28: 2-5
39. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010 ; 69: 325-323
40. Zhang W, Doherty M, Bardin T, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 ; 65: 1312-1324
41. Ambrose JA, Winters SL, Arora RR, et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol. 1985 ; 6: 1233-1238
42. Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in literature. J Clin Epidemiol. 2000 ; 53: 1119-1129